Cargando…
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay
INTRODUCTION: Circulating tumor DNA (ctDNA) detection postoperatively may identify patients with urothelial cancer at a high risk of relapse. Pragmatic tools building off clinical tumor next-generation sequencing (NGS) platforms could have the potential to increase assay accessibility. METHODS: We e...
Autores principales: | Powles, Thomas, Young, Amanda, Nimeiri, Halla, Madison, Russell W., Fine, Alexander, Zollinger, Daniel R., Huang, Yanmei, Xu, Chang, Gjoerup, Ole V., Aushev, Vasily N., Wu, Hsin-Ta, Aleshin, Alexey, Carter, Corey, Davarpanah, Nicole, Degaonkar, Viraj, Gupta, Pratyush, Mariathasan, Sanjeev, Schleifman, Erica, Assaf, Zoe June, Oxnard, Geoffrey, Hegde, Priti S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433150/ https://www.ncbi.nlm.nih.gov/pubmed/37601688 http://dx.doi.org/10.3389/fonc.2023.1221718 |
Ejemplares similares
-
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection
por: Lonardi, Sara, et al.
Publicado: (2022) -
ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma
por: Zhang, Liangliang, et al.
Publicado: (2022) -
Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab
por: Kansara, Maya, et al.
Publicado: (2022) -
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022) -
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)